Viewing Study NCT04310592

Bugs

Ignite Creation Date: 2025-12-24 @ 3:51 PM

Ignite Modification Date: 2026-02-03 @ 5:32 PM

Study NCT ID: NCT04310592

Status: TERMINATED

Last Update Posted: 2024-12-12

First Post: 2020-03-12

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Sponsor: Celularity Incorporated

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions:

Condition Brief	Condition Text	View

None	Leukemia	View
None	Leukemia, Myeloid	View
None	Leukemia, Myeloid, Acute	View
None	Neoplasms by Histologic Type	View
None	Neoplasms	View
None	Immunosuppressive Agents	View
None	Immunologic Factors	View
None	Physiological Effects of Drugs	View
None	Alkylating Agents	View
None	Antimetabolites, Antineoplastic	View
None	Antiviral Agents	View
None	Analgesics, Non-narcotic	View
None	Anti-infective Agents	View
None	Analgesics	View
None	Peripheral Nervous System Agents	View
None	Hematologic Diseases	View
None	Hematologic Neoplasms	View
None	Leukemia in Remission	View
None	Relapsed Adult AML	View
None	Refractory AML	View

Keywords:

Keyword Brief	Keyword Text	View

None	CYNK-001	View
None	Acute Myeloid Leukemia	View
None	Acute Myelogenous Leukemia	View
None	allogeneic	View
None	allogeneic stem cell transplant	View
None	AML	View
None	cell therapy	View
None	cyclophosphamide	View
None	fludarabine	View
None	minimal residual disease	View
None	MRD	View
None	newly diagnosed AML	View
None	newly diagnosed acute myeloid leukemia	View
None	NK cells	View
None	natural killer cells	View
None	fludarabine phosphate	View
None	antineoplastic agents, alkylating	View
None	molecular mechanisms of pharmacological action	View
None	relapsed AML	View
None	refractory AML	View